Official Title: “Effect of Ondansetron for Withdrawal Symptoms”

We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve withdrawal symptoms experienced while the patient is being weaned off opioid medications.

This medication has shown anecdotal evidence of being affective for the treatment of withdrawal symptoms and we hope to determine whether this is affective.

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study

Intervention(s) in this Clinical Trial

• Drug: Ondansetron

Primary Measures

• Decrease of withdrawal symptoms

• Inclusion Criteria:-Over 18 years of age
• No medical contraindications to medication
• Able to fulfill research procedures Exclusion Criteria:-Subjects who are unable to respond to our questionnaires or to stimuli as required by the experimental protocol will be excluded.
• Subjects will be excluded if they have a history of significant psychiatric disorders that would prevent them from engaging in a treatment program.
• Participating in other studies that would interfere with the procedures in this study
• Known or apparent pregnancy

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Stanford University

Overall Clinical Trial Officials and Contacts

Sean Mackey Principal Investigator Stanford University  

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00695864

Study ID Number: SU-05222008-1180

ClinicalTrials.gov Identifier: NCT00695864

Health Authority: United States: Institutional Review Board